CSF2 and Crohn disease: Low GM-CSF bioactivity due to anti-GM-CSF antibodies in Crohn’s Disease is associated with increased gut barrier permeability, microbial translocation, and innate immune activation (48), and it is now accepted that a large number of diverse pathological states are associated with altered gut barrier integrity (49).